Integrated Mathematical Oncology Department Metrics

CLINICAL TRIAL 20117
A Phase 1/2 Study of Regn5678 (Anti-psmaxcd28) with Cemiplimab (Anti-pd-1) in Patients with Metastatic Castration-Resistant Prostate Cancer
Condition: Genitourinary
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); REGN5678 ()

CLINICAL TRIAL 20898
A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)
Condition: Genitourinary
Intervention: Ceralasertib ()

CLINICAL TRIAL 21139
A Phase IIA Study of Sequential ("first strike, second strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for High Risk Metastatic Castration Sensitive Prostate Cancer
Condition: Genitourinary
Intervention: Abiraterone acetate (); Apalutamide (); Decapeptyl SR (Triptorelin); Degarelix (); Eligard (Leuprolide); Enzalutamide (Xtandi); Leuprolide (); Relugolix (Orgovyx); Taxotere (docetaxel); Tislelizumab (); Triptorelin (); Zytiga (Abiraterone acetate); docetaxel (); goserelin acetate (Zoladex); prednisone ()

CLINICAL TRIAL 21266
Gut Metabolome-Can it be Developed As A Biomarker of Response to Immunotherapy in Metastatic Renal Cell Cancer
Condition: Genitourinary
Intervention:

CLINICAL TRIAL 21433
A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cell engager, in patients with therapy refractory metastatic castration resistant prostate cancer
Condition: Genitourinary
Intervention: LAVA-1207 ()

CLINICAL TRIAL 22003
A Phase II Randomized Study of Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer with PSA Progression while on NHA and LHRH Analog
Condition: Genitourinary
Intervention: Abiraterone (); Apalutamide (); Enzalutamide (Xtandi); Provenge (Sipuleucel-T); Sipuleucel-T (); prednisone ()

• Eco-Evolutionary Dynamics of NSCLC to Immunotherapy: Response and Resistance
  Sponsor: Nat Institutes of Health
  PI (Contact):Anderson, A.,PI (MPI):Gatenby, R.
• Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy
  Sponsor: Nat Institutes of Health
  PI (Contact):Enderling, H.,PI (MPI):Pilon-Thomas, S.
• Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
  Sponsor: Nat Institutes of Health
  PI (Contact):Rejniak, K.,PI (MPI):Pilon-Thomas, S.
• Investigating the Feasibility of a First-Strike, Second-Strike Extinction Therapy in ER+ Breast Cancer
  Sponsor: Moffitt Cancer Center
  PI:West, J.,CO-PI:Gomes, A.
• Ventilator IP (20MA021)
  Sponsor: Moffitt Cancer Center
  PI:Enderling, H.
• Developing Mathematical Model Driven Optimized Recurrent Glioblastoma Therapies
  Sponsor: Nat Institutes of Health
  PI (Contact):Enderling, H.,PI (MPI):Yu, M.
• Pilot Project 4-St of FL Funds-COE-Anderson
  Sponsor: Moffitt Cancer Center
  PI:Andor, N.,Core PI/Director:Gomes, A.
• Characterizing Cytotoxic Therapy Induced Shifts in the Cost-to-Benefit Ratio of High Ploidy
  Sponsor: Nat Institutes of Health
  PI:Andor, N.
• A framework to integrate live-cell imaging with single-cell sequencing and learn how cells adapt to new environments
  Sponsor: Nat Institutes of Health
  PI:Andor, N.
• Evolving, understanding and optimising novel Cancer therapies
  Sponsor: US Dept of Energy
  PI:Anderson, A.
• Development of Adoptive T-Cell Therapy in Bladder Cancer Incorporating Patient-Specific Tumor Microenvironment
  Sponsor: US Army
  PI:Rejniak, K.
• The Polyaneuploid Cancer Cell State Mediates Multitherapy Resistance in Cancer
  Sponsor: US Army
  PI:Brown, J.
• Innovative Mathematical Oncology Approaches to Identify Patient-Specific Biomarkers to Personalize Radiation Therapy for Breast Cancer Patients
  Sponsor: Jayne Koskinas & Ted Giovanis Foundation for Health Policy
  PI:Enderling, H.
• Modeling the Role and Regulation of Reactive Stroma in Breast Ductal Carcinoma Microinvasions
  Sponsor: Nat Institutes of Health
  PI:Rejniak, K.
• Adaptive Radiation Fractionation in HPV+ Oropharyngeal Cancer
  Sponsor: Moffitt Cancer Center
  PI:Enderling, H.,CO-PI:Caudell, J.,CO-PI:Torres-Roca, J.

• Kulkarni P, Wiley HS, Levine H, Sauro H, Anderson A, Wong STC, Meyer AS, Iyengar P, Corlette K, Swanson K, Mohanty A, Bhattacharya S, Patel A, Jain V, Salgia R. Addressing the genetic/nongenetic duality in cancer with systems biology. Trends Cancer. 2023 Mar.9(3):185-187. Pubmedid: 36635119.
• El-Kenawi A, Berglund A, Estrella V, Zhang Y, Liu M, Putney RM, Yoder S, Johnson J, Brown J, Gatenby R. Elevated Methionine Flux Drives Pyroptosis Evasion in Persister Cancer Cells. Cancer Res. 2023 Mar.83(5):720-734. Pubmedid: 36480167. Pmcid: PMC9978888.
• Harshe I, Enderling H, Brady-Nicholls R. Predicting Patient-Specific Tumor Dynamics: How Many Measurements Are Necessary?. Cancers (Basel). 2023 Feb.15(5). Pubmedid: 36900161. Pmcid: PMC10000065.
• Bukkuri A, Pienta KJ, Hockett I, Austin RH, Hammarlund EU, Amend SR, Brown JS. Modeling cancer's ecological and evolutionary dynamics. Med Oncol. 2023 Feb.40(4):109. Pubmedid: 36853375. Pmcid: PMC9974726.
• Taleb NN, West J. Working with Convex Responses: Antifragility from Finance to Oncology. Entropy (Basel). 2023 Feb.25(2). Pubmedid: 36832709. Pmcid: PMC9955868.
• Jim HSL, Brady-Nicholls R, Hershman DL. The Importance of Patient-Reported Outcomes in Pragmatic Clinical Trials. J Natl Cancer Inst. 2023 Feb. Pubmedid: 36805254.
• Miroshnychenko D, Miti T, Miller A, Kumar P, Laurie M, Bui MM, Altrock PM, Basanta D, Marusyk A. Paracrine enhancement of tumor cell proliferation provides indirect stroma-mediated chemoresistance via acceleration of tumor recovery between chemotherapy cycles. bioRxiv. 2023 Feb. Pubmedid: 36798328. Pmcid: PMC9934626.
• Kimmel GJ, Beck RJ, Yu X, Veith T, Bakhoum S, Altrock PM, Andor N. Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction. PLoS Comput Biol. 2023 Jan.19(1):e1010815. Pubmedid: 36689467. Pmcid: PMC9917311.
• Freischel AR, Teer JK, Luddy K, Cunningham J, Artzy-Randrup Y, Epstein T, Tsai KY, Berglund A, Cleveland JL, Gillies RJ, Brown JS, Gatenby RA. Evolutionary Analysis of TCGA Data Using Over- and Under- Mutated Genes Identify Key Molecular Pathways and Cellular Functions in Lung Cancer Subtypes. Cancers (Basel). 2022 Dec.15(1). Pubmedid: 36612014. Pmcid: PMC9817988.
• Potratz EJ, Brown JS, Rafacz ML, Santymire RM. Designing an assay to evaluate behavioral responses to opposite-sex conspecifics in the endangered black-footed ferret (Mustela nigripes). Zoo Biol. 2022 Dec. Pubmedid: 36585919.
• Kirtane KS, Zahid MU, Enderling H, Harrison LB. Reimagining Cancer Staging in the Era of Evolutionary Oncology. J Natl Compr Canc Ne. 2022 Dec.20(12):1370-1372. Pubmedid: 36509079.
• West J, Robertson-Tessi M, Anderson ARA. Agent-based methods facilitate integrative science in cancer. Trends Cell Biol. 2022 Nov. Pubmedid: 36404257.
• Bayer P, Brown JS, Dubbeldam J, Broom M. A Markovian decision model of adaptive cancer treatment and quality of life. J Theor Biol. 2022 Nov.551-552:111237. Pubmedid: 35944591.
• Zhang J, Gallaher J, Cunningham JJ, Choi JW, Ionescu F, Chatwal MS, Jain R, Kim Y, Wang L, Brown JS, Anderson AR, Gatenby RA. A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer. Cancers (Basel). 2022 Oct.14(21). Pubmedid: 36358643. Pmcid: PMC9656891.
• Brady-Nicholls R, Enderling H. Range-Bounded Adaptive Therapy in Metastatic Prostate Cancer. Cancers (Basel). 2022 Oct.14(21). Pubmedid: 36358738. Pmcid: PMC9657943.
• Shyntar A, Patel A, Rhodes M, Enderling H, Hillen T. The Tumor Invasion Paradox in Cancer Stem Cell-Driven Solid Tumors. Bull Math Biol. 2022 Oct.84(12):139. Pubmedid: 36301402. Pmcid: PMC9613767.
• Schenck RO, Kim E, Bravo RR, West J, Leedham S, Shibata D, Anderson ARA. Homeostasis limits keratinocyte evolution. Proc Natl Acad Sci U S A. 2022 Aug.119(35). Pubmedid: 35998218. Pmcid: PMC9436311.
• Bukkuri A, Pienta KJ, Austin RH, Hammarlund EU, Amend SR, Brown JS. A life history model of the ecological and evolutionary dynamics of polyaneuploid cancer cells. Sci Rep. 2022 Aug.12(1):13713. Pubmedid: 35962062. Pmcid: PMC9374668.
• Bukkuri A, Pienta KJ, Austin RH, Hammarlund EU, Amend SR, Brown JS. Stochastic models of Mendelian and reverse transcriptional inheritance in state-structured cancer populations. Sci Rep. 2022 Jul.12(1):13079. Pubmedid: 35906318. Pmcid: PMC9338039.
• Prabhakaran S, Gatenbee C, Robertson-Tessi M, West J, Beg AA, Gray J, Antonia S, Gatenby RA, Anderson ARA. Mistic: An open-source multiplexed image t-SNE viewer. Patterns (N Y). 2022 Jul.3(7):100523. Pubmedid: 35845830. Pmcid: PMC9278502.
• Prabhakaran S, Gatenbee C, Anderson ARA. Developing tools for analyzing and viewing multiplexed images. Patterns (N Y). 2022 Jul.3(7):100549. Pubmedid: 35845839. Pmcid: PMC9278522.
• Bekker RA, Zahid MU, Binning JM, Spring BQ, Hwu P, Pilon-Thomas S, Enderling H. Rethinking the immunotherapy numbers game. J Immunother Cancer. 2022 Jul.10(7). Pubmedid: 35793871. Pmcid: PMC9260835.
• Daniel Grass G, Alfonso JCL, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Enderling H, Torres-Roca JF. The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 Jul.113(3):635-647. Pubmedid: 35289298. Pmcid: PMC9250625.
• Bukkuri A, Gatenby RA, Brown JS. GLUT1 production in cancer cells: a tragedy of the commons. NPJ Syst Biol Appl. 2022 Jun.8(1):22. Pubmedid: 35768428. Pmcid: PMC9243083.
• Zhang J, Cunningham J, Brown J, Gatenby R. Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes. Elife. 2022 Jun.11. Pubmedid: 35762577. Pmcid: PMC9239688.
• Bekker RA, Kim S, Pilon-Thomas S, Enderling H. Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune system. Neoplasia. 2022 Jun.28:100796. Pubmedid: 35447601. Pmcid: PMC9043662.
• Pienta KJ, Hammarlund EU, Austin RH, Axelrod R, Brown JS, Amend SR. Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy. Semin Cancer Biol. 2022 Jun.81:145-159. Pubmedid: 33276091.
• Thomas DS, Cisneros LH, Anderson ARA, Maley CC. In Silico Investigations of Multi-Drug Adaptive Therapy Protocols. Cancers (Basel). 2022 May.14(11). Pubmedid: 35681680. Pmcid: PMC9179496.
• Wölfl B, Te Rietmole H, Salvioli M, Kaznatcheev A, Thuijsman F, Brown JS, Burgering B, Staňková K. The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer. Dyn Games Appl. 2022 May.12(2):313-342. Pubmedid: 35601872. Pmcid: PMC9117378.
• Baratchart E, Lo CH, Lynch CC, Basanta D. Integrated computational and in vivo models reveal Key Insights into macrophage behavior during bone healing. PLoS Comput Biol. 2022 May.18(5):e1009839. Pubmedid: 35559958. Pmcid: PMC9106165.
• Anadon CM, Yu X, Hänggi K, Biswas S, Chaurio RA, Martin A, Payne KK, Mandal G, Innamarato P, Harro CM, Mine JA, Sprenger KB, Cortina C, Powers JJ, Costich TL, Perez BA, Gatenbee CD, Prabhakaran S, Marchion D, Heemskerk MHM, Curiel TJ, Anderson AR, Wenham RM, Rodriguez PC, Conejo-Garcia JR. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. 2022 May.40(5):545-557.e13. Pubmedid: 35427494. Pmcid: PMC9096229.
• Gabbutt C, Schenck RO, Weisenberger DJ, Kimberley C, Berner A, Househam J, Lakatos E, Robertson-Tessi M, Martin I, Patel R, Clark SK, Latchford A, Barnes CP, Leedham SJ, Anderson ARA, Graham TA, Shibata D. Fluctuating methylation clocks for cell lineage tracing at high temporal resolution in human tissues. Nat Biotechnol. 2022 May.40(5):720-730. Pubmedid: 34980912. Pmcid: PMC9110299.
• Strobl MAR, Gallaher J, West J, Robertson-Tessi M, Maini PK, Anderson ARA. Spatial structure impacts adaptive therapy by shaping intra-tumoral competition. Commun Med (Lond). 2022 Apr.2:46. Pubmedid: 35603284. Pmcid: PMC9053239.
• Gatenbee CD, Baker AM, Schenck RO, Strobl M, West J, Neves MP, Hasan SY, Lakatos E, Martinez P, Cross WCH, Jansen M, Rodriguez-Justo M, Whelan CJ, Sottoriva A, Leedham S, Robertson-Tessi M, Graham TA, Anderson ARA. Immunosuppressive niche engineering at the onset of human colorectal cancer. Nat Commun. 2022 Apr.13(1):1798. Pubmedid: 35379804. Pmcid: PMC8979971.
• Schenck RO, Brosula G, West J, Leedham S, Shibata D, Anderson AR. Gattaca: Base-Pair Resolution Mutation Tracking for Somatic Evolution Studies using Agent-based Models. Mol Biol Evol. 2022 Apr.39(4). Pubmedid: 35298641. Pmcid: PMC9034688.
• Glazar DJ, Johnson M, Farinhas J, Steuer CE, Saba NF, Bonomi M, Chung CH, Enderling H. Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab. Oral Oncol. 2022 Apr.127:105787. Pubmedid: 35248922.
• Buchsbaum JC, Jaffray DA, Ba D, Borkon LL, Chalk C, Chung C, Coleman MA, Coleman CN, Diehn M, Droegemeier KK, Enderling H, Espey MG, Greenspan EJ, Hartshorn CM, Hoang T, Hsiao HT, Keppel C, Moore NW, Prior F, Stahlberg EA, Tourassi G, Willcox KE. Predictive Radiation Oncology - A New NCI-DOE Scientific Space and Community. Radiat Res. 2022 Apr.197(4):434-445. Pubmedid: 35090025. Pmcid: PMC9058979.
• Foo J, Basanta D, Rockne RC, Strelez C, Shah C, Ghaffarian K, Mumenthaler SM, Mitchell K, Lathia JD, Frankhouser D, Branciamore S, Kuo YH, Marcucci G, Vander Velde R, Marusyk A, Hang S, Hari K, Jolly MK, Hatzikirou H, Poels K, Spilker M, Shtylla B, Robertson-Tessi M, Anderson ARA. Roadmap on plasticity and epigenetics in cancer. Phys Biol. 2022 Apr.19(3). Pubmedid: 35078159. Pmcid: PMC9190291.
• Andor N, Altrock PM, Jain N, Gomes AP. Tipping Cancer Cells Over the Edge: The Context-Dependent Cost of High Ploidy. Cancer Res. 2022 Mar.82(5):741-748. Pubmedid: 34785577. Pmcid: PMC8898264.
• Enderling H. Mathematical oncology: A new frontier in cancer biology and clinical decision making: Comment on "Improving cancer treatments via dynamical biophysical models" by M. Kuznetsov, J. Clairambault & V. Volpert. Phys Life Rev. 2022 Mar.40:60-62. Pubmedid: 34857476.
• Mandal G, Biswas S, Anadon CM, Yu X, Gatenbee CD, Prabhakaran S, Payne KK, Chaurio RA, Martin A, Innamarato P, Moran C, Powers JJ, Harro CM, Mine JA, Sprenger KB, Rigolizzo KE, Wang X, Curiel TJ, Rodriguez PC, Anderson ARA, Saglam O, Conejo-Garcia JR. IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer. Cancer Res. 2022 Mar.82(5):859-871. Pubmedid: 34949671. Pmcid: PMC8898267.
• Brüningk SC, Peacock J, Whelan CJ, Brady-Nicholls R, Yu HM, Sahebjam S, Enderling H. Author Correction: Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements. Sci Rep. 2022 Mar.12(1):4441. Pubmedid: 35292722. Pmcid: PMC8924186.